AlphaQuest LLC Makes New Investment in Kodiak Sciences Inc. (NASDAQ:KOD)

AlphaQuest LLC bought a new position in Kodiak Sciences Inc. (NASDAQ:KOD) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,681 shares of the company’s stock, valued at approximately $256,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GSA Capital Partners LLP bought a new position in Kodiak Sciences during the 3rd quarter valued at about $751,000. Peapod Lane Capital LLC purchased a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $1,660,000. RIA Advisory Group LLC bought a new position in Kodiak Sciences during the third quarter valued at approximately $191,000. FMR LLC boosted its holdings in Kodiak Sciences by 26.4% in the third quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after purchasing an additional 41,987 shares during the last quarter. Finally, Barclays PLC grew its position in Kodiak Sciences by 65.5% in the 3rd quarter. Barclays PLC now owns 79,658 shares of the company’s stock worth $208,000 after purchasing an additional 31,527 shares during the period. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Trading Up 5.5 %

Shares of KOD stock opened at $3.64 on Friday. Kodiak Sciences Inc. has a 12 month low of $2.19 and a 12 month high of $11.60. The stock has a market cap of $191.55 million, a P/E ratio of -1.00 and a beta of 2.26. The company has a 50 day simple moving average of $5.90 and a two-hundred day simple moving average of $5.37.

Analyst Ratings Changes

Separately, Jefferies Financial Group upgraded Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Monday, December 9th.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.